Genflow Completes Dosing Phase of SIRT6 Gene Therapy Trial in Dogs with No Adverse Events
Key Insights
Genflow Biosciences (search) successfully completed the dosing phase of its canine clinical trial for SIRT6 (search)-based gene therapy, with all enrolled dogs receiving the full administration without any adverse events.
The blinded clinical trial demonstrated a strong safety and tolerability profile, with no serious, moderate, or minor side effects observed during the dosing phase.
First efficacy results are expected in mid-to-late January 2026, including blood analyses and muscle biopsies to evaluate therapeutic benefits for sarcopenia (search) and healthspan biomarkers.
Genflow Biosciences (search) has achieved a significant milestone in its longevity gene therapy program, successfully completing the dosing phase of its canine clinical trial for SIRT6 (search)-based gene therapy. All dogs enrolled in the ongoing study received the full administration of the company's investigational therapy without any reported adverse events, demonstrating a promising safety profile for this novel approach to extending healthspan.
Strong Safety Profile Demonstrated
The biotechnology company reported that no serious, moderate, or minor side effects were observed during the dosing phase, reinforcing the strong safety and tolerability profile of their SIRT6 (search)-based gene therapy. This safety milestone represents a crucial step forward for Genflow's longevity program, which focuses on extending healthspan through advanced gene therapies.
"These milestones represent an important step forward for our longevity program. The absence of any adverse events is highly encouraging and reinforces the strong safety profile of our approach," commented Dr. Eric Leire, CEO of Genflow.
Trial Design and Timeline
The study is being conducted as a blinded clinical trial, preventing efficacy assessment during the dosing phase. Dogs enrolled in the trial will continue to be monitored for a total duration of 180 days, allowing researchers to evaluate both short-term and longer-term effects of the gene therapy.
Genflow expects to report first efficacy results in mid-to-late January 2026, which will include comprehensive blood analyses and muscle biopsies. These assessments will evaluate potential therapeutic benefits related to sarcopenia (search), overall healthspan, and lifespan-associated biomarkers.
A second efficacy assessment is planned at the six-month timepoint, with results expected in June-July 2026, to evaluate the durability and longer-term effects of the gene therapy.
Commercial Opportunities
Following analysis of the efficacy data, Genflow intends to resume discussions with several animal health companies for potential early-stage licensing opportunities. The company has already engaged with parties under confidentiality and data access agreements, positioning itself for potential partnerships in the animal health sector.
About the Technology
Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 (search) gene, which has yielded promising preclinical results. The 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025.
The company, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process. Their approach aims to promote longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population.